糖尿病網膜症(DR)の世界市場:タイプ別(増殖性DR、非増殖性DR)、治療法別(VEGF阻害剤、ステロイド療法、レーザー光凝固術、硝子体手術)

Allied Market Researchが発行した調査報告書(AMR8040550)
◆英語タイトル:Diabetic Retinopathy Market by Type [Proliferative DR and Non-Proliferative DR), by Management Type (Anti VEGF Drug, Intra-ocular Steroid Injections, Laser Surgeries, and Vitrectomy) - Global Opportunity Analysis and Industry Forecast, 2014-2022
◆商品コード:AMR8040550
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2017年4月
◆ページ数:150
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:Medical Devices & Supplies
◆販売価格オプション(消費税別)
Single UserUSD4,999 ⇒換算¥564,887見積依頼/購入/質問フォーム
5 UserUSD6,229 ⇒換算¥703,849見積依頼/購入/質問フォーム
Enterprise UserUSD6,979 ⇒換算¥788,582見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

本資料は、糖尿病網膜症(DR)の世界市場について調べ、糖尿病網膜症(DR)の世界規模、市場シェア、市場動向、市場環境、タイプ別(増殖性DR、非増殖性DR)分析、治療法別(VEGF阻害剤、ステロイド療法、レーザー光凝固術、硝子体手術)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・糖尿病網膜症(DR)の世界市場概要
・糖尿病網膜症(DR)の世界市場環境
・糖尿病網膜症(DR)の世界市場動向
・糖尿病網膜症(DR)の世界市場規模
・糖尿病網膜症(DR)の世界市場:市場シェア
・糖尿病網膜症(DR)の世界市場:タイプ別(増殖性DR、非増殖性DR)
・糖尿病網膜症(DR)の世界市場:治療法別(VEGF阻害剤、ステロイド療法、レーザー光凝固術、硝子体手術)
・糖尿病網膜症(DR)の世界市場:地域別市場規模・分析
・糖尿病網膜症(DR)の北米市場規模・予測
・糖尿病網膜症(DR)のアメリカ市場規模・予測
・糖尿病網膜症(DR)のヨーロッパ市場規模・予測
・糖尿病網膜症(DR)のアジア市場規模・予測
・糖尿病網膜症(DR)の日本市場規模・予測
・糖尿病網膜症(DR)の中国市場規模・予測
・関連企業情報
【レポートの概要】

Diabetic retinopathy (DR) is a medical condition of the eye, which is prevalent in a diabetic individual. It is mainly caused due to damage of the blood vessels of the light-sensitive tissue present at the back of the eye. Without timely treatment, the disease may lead to bleeding in the eyes, cloudy vision, and may even destroy the retina. DR is amongst the common cause of loss of vision in the diabetic population. From 1990 to 2010, DR holds the fifth position among the most common causes of preventable blindness and severe visual impairment.

The global diabetic retinopathy market was valued at $966 million in 2015, and is expected to reach $2,490 million by 2022, growing at a CAGR of 14.4% during the forecast period. The market is expected to witness significant growth during the forecast period due to increase in prevalence of diabetes worldwide, rise in geriatric population, growth in incidence of blindness due to diabetes, and augment in focus on awareness which facilitates early diagnosis to control the diseases. Although these factors garner the growth of the market, dearth of skilled ophthalmologists and extended approval time for drugs limit it. On the other hand, emergence of combined therapies for treatment of diabetic macular edema, and the emerging markets of the Asia-Pacific and LAMEA regions are projected to provide several opportunities for the market growth.

The diabetic retinopathy market is segmented on the basis of type, treatment type, and region. Based on type, the market is bifurcated into proliferative DR and diabetic macular edema (DME). On the basis of treatment type, diabetic retinopathy market is segmented into anti VEGF drug, steroid implants, laser surgeries, and vitrectomy. The market is analyzed based on four geographical regions, which include North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

This report provides an extensive analysis of the current and emerging market trends and dynamics in the global diabetic retinopathy market.
Comprehensive analysis of geographical regions is provided to determine the prevailing opportunities in the market.
This study provides the competitive landscape of the market to predict the competitive environment across geographies.
This report entails the detailed quantitative analysis of the current market and estimations from 2014 to 2022 to identify the prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
Region- and country-wise diabetic retinopathy market conditions are comprehensively analyzed in the report to understand the regional trends and dynamics.

Diabetic Retinopathy Market Key Segments:

By Type

Proliferative Diabetic Retinopathy
Diabetic Macular Edema (DME)

By Treatment Type

Anti VEGF Drug
Steroid Implants
Laser Surgeries
Vitrectomy

By Region

North America
U.S.
Canada
Mexico
Europe
France
Germany
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Abbott Laboratories
Alimera Science
Allergan plc
Ampio Pharmaceuticals.
Bayer AG
F. Hoffmann-La Roche
Novartis International AG
Pfizer
Regeneron Pharmaceuticals Inc.
Valeant Pharmaceutical

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

Boehringer Ingelheim GmbH
KOWA Company, Ltd.
BCN Peptides S.A.
ThromboGenics NV

【レポートの目次】

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Competitive intelligence of companies and their strategies

3.3. MARKET SHARE ANALYSIS, 2015
3.4. MARKET DYNAMICS

3.4.1. Drivers

3.4.1.1. Growing prevalence of diabetes
3.4.1.2. Increasing incidence of blindness due to diabetes
3.4.1.3. Growing geriatric population
3.4.1.4. Increasing awareness for treatment of diabetic retinopathy

3.4.2. Restraints

3.4.2.1. Extended approval time for drugs
3.4.2.2. Dearth of skilled ophthalmologists

3.4.3. Opportunities

3.4.3.1. Lucrative opportunities in the emerging economies
3.4.3.2. Emergence of combined therapies

3.4.4. Impact analysis

3.5. CLINICAL TRIALS

CHAPTER 4 DIABETIC RETINOPATHY MARKET, BY TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. PROLIFERATIVE DIABETIC RETINOPATHY

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. DIABETIC MACULAR EDEMA

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

CHAPTER 5 DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ANTI-VEGF DRUG

5.2.1. Market size and forecast

5.3. STEROID IMPLANTS

5.3.1. Market size and forecast

5.4. LASER SURGERIES

5.4.1. Market size and forecast

5.5. VITRECTOMY

5.5.1. Market size and forecast

CHAPTER 6 DIABETIC RETINOPATHY MARKET, BY REGION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.4. U.S.
6.2.5. Canada
6.2.6. Mexico

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.4. Germany
6.3.5. France
6.3.6. UK
6.3.7. Italy
6.3.8. Spain
6.3.9. Rest of Europe

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.4. Japan
6.4.5. China
6.4.6. India
6.4.7. South Korea
6.4.8. Australia
6.4.9. Rest of Asia-Pacific

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.4. Brazil
6.5.5. South Africa
6.5.6. Saudi Arabia
6.5.7. Rest of LAMEA

CHAPTER 7 COMPANY PROFILES

7.1. ABBOTT LABORATORIES

7.1.1. Overview
7.1.2. Operating business segments
7.1.3. Business performance
7.1.4. Key strategic moves and developments

7.2. ALIMERA SCIENCE

7.2.1. Overview
7.2.2. Operating business segments
7.2.3. Business performance
7.2.4. Key strategic moves and developments

7.3. ALLERGAN PLC

7.3.1. Overview
7.3.2. Operating business segments
7.3.3. Business performance
7.3.4. Key strategic moves and developments

7.4. AMPIO PHARMACEUTICALS.

7.4.1. Company overview
7.4.2. Operating business segments
7.4.3. Business performance
7.4.4. Key strategic moves and developments

7.5. BAYER AG

7.5.1. Overview
7.5.2. Operating business segments
7.5.3. Business performance
7.5.4. Key strategic moves and developments

7.6. F. HOFFMANN-LA ROCHE

7.6.1. Company overview
7.6.2. Operating business segments
7.6.3. Business performance
7.6.4. Key strategic moves and developments

7.7. NOVARTIS INTERNATIONAL AG

7.7.1. Overview
7.7.2. Operating business segments
7.7.3. Business performance
7.7.4. Key strategic moves and developments

7.8. PFIZER

7.8.1. Overview
7.8.2. Operating business segments
7.8.3. Business performance
7.8.4. Key strategic moves and developments

7.9. REGENERON PHARMACEUTICALS INC.

7.9.1. Company overview
7.9.2. Operating business segments
7.9.3. Business performance
7.9.4. Key strategic moves and developments

7.10. VALEANT PHARMACEUTICAL

7.10.1. Overview
7.10.2. Operating business segments
7.10.3. Business performance
7.10.4. Key strategic moves and developments

TABLE 1. GLOBAL DIABETIC RETINOPATHY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 2. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
TABLE 3. GLOBAL DIABETIC MACULAR EDEMA (DME) MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
TABLE 4. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 5. GLOBAL DIABETIC MACULAR EDEMA (DME) MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 6. GLOBAL DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
TABLE 7. GLOBAL ANTI VEGF MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2014-2022 ($MILLION)
TABLE 8. GLOBAL STEROID IMPLANTS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2014-2022 ($MILLION)
TABLE 9. GLOBAL LASER SURGERIES MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2014-2022 ($MILLION)
TABLE 10. GLOBAL VITRECTOMY MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2014-2022 ($MILLION)
TABLE 11. GLOBAL DIABETIC RETINOPATHY MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 12. NORTH AMERICA DIABETIC RETINOPATHY MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 13. NORTH AMERICA DIABETIC RETINOPATHY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 14. NORTH AMERICA DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
TABLE 15. EUROPE DIABETIC RETINOPATHY MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 16. EUROPE DIABETIC RETINOPATHY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 17. EUROPE DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
TABLE 18. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 19. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 20. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
TABLE 21. LAMEA DIABETIC RETINOPATHY MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 22. LAMEA DIABETIC RETINOPATHY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 23. LAMEA DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
TABLE 24. ABBOTT: COMPANY SNAPSHOT
TABLE 25. ALIMERA: COMPANY SNAPSHOT
TABLE 26. ALLERGAN: COMPANY SNAPSHOT
TABLE 27. AMPIO: COMPANY SNAPSHOT
TABLE 28. BAYER: COMPANY SNAPSHOT
TABLE 29. ROCHE: COMPANY SNAPSHOT
TABLE 30. NOVARTIS: COMPANY SNAPSHOT
TABLE 31. PFIZER: COMPANY SNAPSHOT
TABLE 32. REGENERON PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 33. VALEANT PHARMACEUTICAL: COMPANY SNAPSHOT

FIGURE 1. DIABETIC RETINOPATHY MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2014-2016)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5. TOP COMPANIES AND THEIR STRATEGIES
FIGURE 6. DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIGURE 7. DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIGURE 8. MARKET SHARE ANALYSIS, DIABETIC RETINOPATHY MARKET, 2015
FIGURE 9. IMPACT ANALYSIS: DIABETIC RETINOPATHY MARKET
FIGURE 10. CLINICAL TRIALS FOR DIABETIC RETINOPATHY (%)
FIGURE 11. GLOBAL DIABETIC RETINOPATHY MARKET, BY TYPE, 1014-1011 ($MILLION)
FIGURE 12. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 1014-1011 ($MILLION)
FIGURE 13. GLOBAL DIABETIC MACULAR EDEMA (DME) MARKET, BY TREATMENT TYPE, 1014-1011 ($MILLION)
FIGURE 14. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET, BY REGION, 1014-1011 ($MILLION)
FIGURE 15. GLOBAL DIABETIC MACULAR EDEMA (DME) MARKET, BY REGION, 1014-1011 ($MILLION)
FIGURE 16. GLOBAL DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 1014-1011 ($MILLION)
FIGURE 17. GLOBAL ANTI VEGF MARKET FOR DIABETIC RETINOPATHY, BY REGION, 1014-1011 ($MILLION)
FIGURE 18. GLOBAL STEROID IMPLANTS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 1014-1011 ($MILLION)
FIGURE 19. GLOBAL LASER SURGERIES MARKET FOR DIABETIC RETINOPATHY, BY REGION, 1014-1011 ($MILLION)
FIGURE 20. GLOBAL VITRECTOMY MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2014-2022 ($MILLION)
FIGURE 21. GLOBAL DIABETIC RETINOPATHY MARKET, BY REGION, 2014-2022 ($MILLION)
FIGURE 22. NORTH AMERICA DIABETIC RETINOPATHY MARKET, BY COUNTRY, 2014-2022 ($MILLION)
FIGURE 23. NORTH AMERICA DIABETIC RETINOPATHY MARKET, BY TYPE, 2014-2022 ($MILLION)
FIGURE 24. NORTH AMERICA DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
FIGURE 25. U.S. DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 26. CANADA DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 27. MEXICO DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 28. EUROPE DIABETIC RETINOPATHY MARKET, BY COUNTRY, 2014-2022 ($MILLION)
FIGURE 29. EUROPE DIABETIC RETINOPATHY MARKET, BY TYPE, 2014-2022 ($MILLION)
FIGURE 30. EUROPE DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
FIGURE 30. GERMANY DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 31. FRANCE DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 32. UK DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 33. ITALY DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 34. SPAIN DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 35. REST OF EUROPE DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 36. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET, BY COUNTRY, 2014-2022 ($MILLION)
FIGURE 37. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET, BY TYPE, 2014-2022 ($MILLION)
FIGURE 38. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
FIGURE 39. JAPAN DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 40. CHINA DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 41. INDIA DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 42. SOUTH KOREA DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 43. AUSTRALIA DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 44. REST OF ASIA-PACIFIC DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 45. LAMEA DIABETIC RETINOPATHY MARKET, BY COUNTRY, 2014-2022 ($MILLION)
FIGURE 46. LAMEA DIABETIC RETINOPATHY MARKET, BY TYPE, 2014-2022 ($MILLION)
FIGURE 47. LAMEA DIABETIC RETINOPATHY MARKET, BY TREATMENT TYPE, 2014-2022 ($MILLION)
FIGURE 48. BRAZIL DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 49. SOUTH AFRICA DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 50. SAUDI ARABIA DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022
FIGURE 51. REST OF LAMEA DIABETIC RETINOPATHY MARKET ($MILLION), 2014-2022

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 糖尿病網膜症(DR)の世界市場:タイプ別(増殖性DR、非増殖性DR)、治療法別(VEGF阻害剤、ステロイド療法、レーザー光凝固術、硝子体手術)(Diabetic Retinopathy Market by Type [Proliferative DR and Non-Proliferative DR), by Management Type (Anti VEGF Drug, Intra-ocular Steroid Injections, Laser Surgeries, and Vitrectomy) - Global Opportunity Analysis and Industry Forecast, 2014-2022)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆